Skip to main content
Premium Trial:

Request an Annual Quote

Cequent to Receive European, Korean Patents on RNAi Technology

Premium

Cequent Pharmaceuticals said this week that it has received notices that the European Patent Office and the Korean Intellectual Property Office intend to grant patents covering the company's core RNAi technology.

The patent applications, entitled "Compositions for Bacterial-Mediated Gene Silencing and Methods Using the Same," relate to Cequent's so-called transkingdom RNAi technology, which involves using attenuated Escherichia coli to transcribe therapeutic shRNAs.

Specifically, the IP claims "attenuated bacteria as a therapeutic engine for the delivery of short interfering RNA molecules against disease-related genes, including cancer genes such as beta-catenin, whose up-regulation is implicated in the formation and proliferation of colorectal and other cancers," Cequent said.

The Scan

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.

Sequencing Study Leads to Vaccine Target in Bacteria Behind Neonatal Meningitis

Researchers eBioMedicine track down potential vaccine targets with transposon sequencing on mutant bacteria causing neonatal meningitis in mouse models of the disease.

Multiple Myeloma Progression Influenced by Immune Microenvironment Expression

Researchers in NPJ Genomic Medicine compare RNA sequencing profiles of 102,207 individual cells in bone marrow samples from 18 individuals with rapid or non-progressing multiple myeloma.

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.